Skip to main content
Clinical Trials/CTRI/2016/08/007226
CTRI/2016/08/007226
Recruiting
Phase 4

A Prospective, Multi Centre, Observational, Data Collection Registry Study To Monitor The Routine Clinical Use Of Mabtas (Rituximab 100 Mg / 500 Mg Concentrate For Solution For Infusion, Manufactured By Intas Pharmaceuticals Ltd) In Indian Patients. - Mabtas registry

Intas Pharmaceuticals Limited0 sites1,000 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Intas Pharmaceuticals Limited
Enrollment
1000
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Adult male or female patients, newly diagnosed with NHL and CLL, and who require treatment with MABTAS therapy will be enrolled.
  • 2\. The diagnosis and staging of NHL \& CLL should be confirmed on the basis of pathology report available with the patients. However, patient of NHL should have one measurable lesion (Nodal lesion: 1\.5 cm in longest diameter or non\-nodal: \>1\.0 x 1\.0 cm) as per International Working Group Response Criteria for Malignant Lymphoma.
  • 3\. Patients willing to provide informed consent.

Exclusion Criteria

  • 1\. Patients with any history or presence of clinically significant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease or any other condition which in the opinion of the investigator could jeopardize the safety of the subject or the validity of the study results.
  • 2\.Patient with a history of hypersensitivity reactions or contraindication to the excipients of planned chemotherapy regimen.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
An observational, prospective, multi-centre, natural history study of patients with mucopolysaccharidosis type IIIAor Mucopolysaccharidosis type III (MPS III)Sanfilippo syndrome10083624
NL-OMON46191ysogene SA5
Recruiting
Not Applicable
High-Frequency Spinal Cord Stimulation at 10kHz (HF10 SCS) for the Treatment of Pelvic Pain PatientsHigh-frequency spinal cord stimulation in patients with chronic, intractable pelvic pain.Reproductive Health and Childbirth - Other reproductive health and childbirth disordersMusculoskeletal - Other muscular and skeletal disordersRenal and Urogenital - Other renal and urogenital disorders
ACTRN12614000989640Dr. Bruce Mitchell30
Recruiting
Not Applicable
High-Frequency Spinal Cord Stimulation at 10kHz (HF10 SCS) for the Treatment of Post-Surgery Back Pain PatientsHigh-frequency spinal cord stimulation in patients with chronic back pain +/- leg pain following spine surgeryMusculoskeletal - Other muscular and skeletal disordersNeurological - Other neurological disordersPhysical Medicine / Rehabilitation - Other physical medicine / rehabilitation
ACTRN12614000665639Dr. Paul Verrills100
Completed
Not Applicable
Prospective, non-randomised, multi-centre, observational study to confirm the performance of Misago® peripheral self-expanding stent system for the treatment of occluded or stenotic superficial femoral or popliteal arteriesOccluded or stenotic superficial femoral and/or popliteal arteriesCirculatory SystemArterial embolism and thrombosis
ISRCTN58138617Terumo Europe N.V. (Belgium)500
Completed
Not Applicable
A Multicentre, Prospective, Longitudinal, Observational Natural History Study to Evaluate Disease Progression in Subjects with Usher Syndrome type 1B (USH1B)Usher syndrome type 1B10015917
NL-OMON46147Oogziekenhuis Rotterdam10